Reconstituted dry powder formulations of ZnO-adjuvanted ovalbumin induce equivalent antigen specific antibodies but lower T cell responses than ovalbumin adjuvanted with Alhydrogel® or cationic adjuvant formulation 01 (CAF®01)
ZnO佐剂卵清蛋白重组干粉制剂诱导等效抗原特异性抗体，但T细胞应答低于Alhydrogel®或阳离子佐剂制剂01（CAF®01）佐剂的卵清蛋白
📄 英文摘要 English Abstract
Most licensed human vaccines are based on liquid dosage forms but have poor storage stability and require continuous and expensive cold-chain storage. In contrast, the use of solid vaccine dosage forms produced by for example spray drying, extends shelf life and eliminates the need for a cold chain. Zinc oxide (ZnO)-based nanoparticles display immunomodulatory properties, but their adjuvant effect as a dry powder formulation is unknown. Here, we show that reconstituted dry powder formulations of ZnO particles containing the model antigen ovalbumin (OVA) induce antigen-specific CD8
📄 中文摘要 Chinese Abstract
📋 英文结构化总结 English Structured Summary
摘要整理
Background:
Most licensed human vaccines are based on liquid dosage forms but have poor storage stability and require continuous and expensive cold-chain storage. In contrast, the use of solid vaccine dosage forms produced by for example spray drying, extends shelf life and eliminates the need for a cold chain. Zinc oxide (ZnO)-based nanoparticles display immunomodulatory properties, but their adjuvant effect as a dry powder formulation is unknown.
Methods:
The methodology involved reconstituted dry powder formulations of ZnO particles containing the model antigen ovalbumin (OVA). No further methodological details are provided in the abstract.
Results:
Reconstituted dry powder formulations of ZnO particles containing the model antigen ovalbumin (OVA) induce antigen-specific CD8.
Data Summary:
No quantitative results or key statistics are reported in the abstract; only the qualitative finding that the formulations induce antigen-specific CD8.
Conclusions:
The study shows that reconstituted dry powder formulations of ZnO particles containing OVA induce antigen-specific CD8.
Practical Significance:
The use of solid vaccine dosage forms extends shelf life and eliminates the need for a cold chain. Zinc oxide (ZnO)-based nanoparticles display immunomodulatory properties.
📋 中文结构化总结 Chinese Structured Summary
背景:
大多数已获批的人用疫苗均为液体制剂，但其储存稳定性较差，需要持续且昂贵的冷链储存。相比之下，采用喷雾干燥等工艺制备的固体疫苗剂型可延长保质期并消除对冷链的需求。氧化锌（ZnO）基纳米颗粒具有免疫调节特性，但其作为干粉制剂的佐剂效果尚不明确。
方法:
研究方法涉及将含有模型抗原卵清蛋白（OVA）的氧化锌颗粒制备成干粉制剂后进行复溶。摘要中未提供进一步的方法学细节。
结果:
含有模型抗原卵清蛋白（OVA）的氧化锌颗粒干粉制剂复溶后可诱导抗原特异性CD8。
数据摘要:
摘要中未报告定量结果或关键统计数据，仅定性描述了该制剂可诱导抗原特异性CD8。
结论:
本研究表明，含有OVA的氧化锌颗粒干粉制剂复溶后可诱导抗原特异性CD8。
实际意义:
固体疫苗剂型的使用可延长保质期并消除对冷链的需求。氧化锌（ZnO）基纳米颗粒具有免疫调节特性。